1. Home
  2. PLBY vs ACOG Comparison

PLBY vs ACOG Comparison

Compare PLBY & ACOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

PLBY

PLBY Group Inc.

HOLD

Current Price

$1.93

Market Cap

139.8M

ML Signal

HOLD

Logo Alpha Cognition Inc.

ACOG

Alpha Cognition Inc.

HOLD

Current Price

$6.18

Market Cap

130.9M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
PLBY
ACOG
Founded
1953
2000
Country
United States
Canada
Employees
N/A
N/A
Industry
Recreational Games/Products/Toys
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
139.8M
130.9M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
PLBY
ACOG
Price
$1.93
$6.18
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
1
Target Price
$3.00
$18.00
AVG Volume (30 Days)
569.1K
96.0K
Earning Date
11-12-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$119,510,000.00
$7,427,199.00
Revenue This Year
$5.20
N/A
Revenue Next Year
$8.32
$101.16
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.90
$3.75
52 Week High
$2.44
$11.54

Technical Indicators

Market Signals
Indicator
PLBY
ACOG
Relative Strength Index (RSI) 74.20 47.68
Support Level $1.57 $5.66
Resistance Level $1.73 $6.20
Average True Range (ATR) 0.11 0.47
MACD 0.05 0.08
Stochastic Oscillator 97.66 69.59

Price Performance

Historical Comparison
PLBY
ACOG

About PLBY PLBY Group Inc.

Playboy Inc, formerly PLBY Group Inc connects consumers around the world with products, services, and experiences to help them look good, feel good, and have fun. PLBY Group serves consumers in four categories: Style and Apparel, Digital Entertainment and Lifestyle, Sexual Wellness, and Beauty and Grooming. It operates through three segments Direct-to-Consumer, Licensing, and Digital Subscriptions and Content. It generates revenue through the sales of products and content services to consumers.

About ACOG Alpha Cognition Inc.

Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, for which there are limited or no treatment options. The Company's current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Company's commercial development program for ZUNVEYL is primarily focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.

Share on Social Networks: